Lupin has received approval for its Meloxicam Capsules, 5 mg and 10 mg, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Vivlodex Capsules, 5 mg and 10 mg, of Zyla Life Sciences US, Inc. The product would be manufactured at company’s Aurangabad facility, India, and is expected to be launched shortly.
Meloxicam Capsules, 5 mg and 10 mg, are indicated for management of osteoarthritis (OA) pain. Meloxicam Capsules (RLD: Vivlodex) had an annual sales of approximately $14 million in the US (IQVIA MAT March 2020).
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1903.00 |
| Dr. Reddys Labs. | 1354.60 |
| Cipla | 1450.05 |
| Zydus Lifesciences | 1152.50 |
| Lupin | 2494.60 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: